drugset / Trial / NCT06209736
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of OMS906 in patients with C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)
Timeline
- Start
- 2024-03-01
- Primary completion
- 2026-01
- Completion
- 2026-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZALTENIBART | Monoclonal antibody | 5 mg/kg | Intravenous |